Small molecule inhibitors of bacterial quorum sensing and biofilm formation

Journal of the American Chemical Society

Volumn 127, Issue 37, 2005, Pages 12762-12763

  Geske, Grant D ^a   Wezeman, Rachel J ^a   Siegel, Adam P ^a   Blackwell, Helen E ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BROMOPHENYL N ACYL HOMOSERINE LACTONE; INDOLE N ACYL HOMOSERINE LACTONE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL PHENOMENA AND FUNCTIONS; BACTERIUM; BIOFILM; DRUG SYNTHESIS; GRAM NEGATIVE BACTERIUM; NONHUMAN; PSEUDOMONAS AERUGINOSA; QUORUM SENSING;

BACTERIAL PROTEINS; BIOFILMS; ENZYME INHIBITORS; HOMOSERINE; LACTONES; LIGANDS; MICROWAVES; MOLECULAR CONFORMATION; PSEUDOMONAS AERUGINOSA;

EID: 25144448174     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja0530321     Document Type: Article

References (22)

1. For a recent review, see: Miller, M. B.; Bassler, B. L. Annu. Rev. Microbiol. 2001, 55, 165-199.
2. Hall-Stoodley, L.; Costerton, J. W.; Stoodley, P. Nat. Rev. Microbiol. 2004, 2, 95-108.
3. Smith, R. S.; Iglewski, B. H. Curr. Opin. Microbiol. 2003, 6, 56-60.
4. (a) Lyon, G. J.; Muir, T. W. Chem. Biol. 2003, 10, 1007-1021 .
5. For two recent examples, see: (b) Glansdorp, F. G.; Thomas, G. L.; Lee, J. J. K.; Dutton, J. M.; Salmond, G. P. C.; Welch, M.; Spring, D. R. Org. Biomol. Chem. 2004, 2, 3329-3336.
6. (c) Smith, K. M.; Bu, Y.; Suga, H. Chem. Biol. 2003, 10, 563-571.
7. Fuqua, C.; Greenberg, E. P. Nat Rev. Mol. Cell Biol. 2002, 3, 685-695.
8. See: (a) Eberhard, A.; Schineller, J. B. Methods Enzymol. 2000, 305, 301-315 and references therein,
9. (b) Castang, S.; Chantegrel, B.; Deshayes, C.; Dolmazon, R.; Gouet, P.; Haser, R.; Reverchon, S.; Nasser, W.; Hugouvieux-Cotte-Pattat, N.; Doutheau, A. Bioorg. Med. Chem. Lett. 2004, 14, 5145-5149.
10. (c) Zhu, J.; Beaber, J. W.; More, M. I.; Fuqua, C.; Eberhard, A.; Winans, S. C. J. Bacteriol. 1998, 180, 5398-5405.
11. Ley, S. V.; Baxendale, I. R. Nat. Rev. Drug Discovery 2002, 1, 573-586.
12. (a) Blackwell, H. E. Org. Biomol. Chem. 2003, 1, 1251-1255.
13. (b) Kappe, C. O. Angew. Chem., Int. Ed. 2004, 43, 6250-6284.
14. All MW-assisted reactions were performed in a commercial MW reactor.
15. Protected β-keto acids were synthesized using established procedures: Rathke, M. W.; Nowak, M. A. Synth. Commun. 1985, 15, 1039-1049.
16. (a) Ko, D. H.; Kim, D. J.; Lyu, C. S.; Min, I. K.; Moon, H.-s. Tetrahedron Lett. 1998, 39, 297-300.
17. (b) Kappel, J. C.; Barany, G. J. Comb. Chem. 2005, 7, 78-84 and references therein.
18. AHLs generated via Scheme 1 were isolated in high enantiopurity (ca. >95%); see Supporting Information.
19. Zhang, R. G.; Pappas, T.; Brace, J. L.; Miller, P. C.; Oulmassov, T.; Molyneaux, J. M.; Anderson, J. C.; Bashkin, J. K.; Winans, S. C.; Joachimiak, A. Nature 2002, 417, 971-974.
20. De Kievit, T. R.; Gillis, R.; Marx, S.; Brown, C.; Iglewski, B. H. Appl. Environ. Microbiol. 2001, 67, 1865-1873.
21. The non-native AHLs failed to activate LasR or TraR at levels similar to or greater than the native ligand (8b or 8d); see Supporting Information (Figures S-3 and S-4). No ligand had an appreciable effect on bacterial growth over an 18-48 h period.
22. See Supporting Information for full dose response data and IC50 values at 100 nM 8b in A. tumefaciens and 1 μM 8d in P. aeruginosa.